IRCT2017080520715N3 IRCT 2017-09-05 Vice chancellor for research, Arak University of Medical Sciences Clinical Trial Study of the Effect of Apripitant Drug on Nausea and Vomiting Due to Chemotherapy in Children The Effect of Aprepitant on Chemo-Induced Nausea and Vomiting in Children with Cancer 2017-08-23 anticipated 60 Complete https://irct.ir/trial/18312 interventional Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment. 3 nausea and vomiting. Intervention 1: Each patient receives the same for an hour before the first course of 40 mg/kg body weight chemotherapy in the form of a single dose of granisetron to a maximum dose of 3 mg per dose plus placebo on days 2 and 3, then the same in the second course of chemotherapy with the same chemotherapy regimen, in addition to granisetron to prevent nausea and vomiting, 125 mg of apripitant for patients 12 to 18 years of age and 3 mg per kg of body weight (eventually up to 125 mg) for ages 5 to 12 years on the first day and 80 mg for children 12 to 18 years and 2 mg per kg body weight (ultimately up to 80 mg) for age 5 to 12 years will receive in the second and third days. In the control group, similar placebo was used. Intervention 2: In the control group, similar placebo was used.